candesartan has been researched along with eprosartan in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 19 (70.37) | 29.6817 |
| 2010's | 6 (22.22) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR | 1 |
| Schieffer, B; Schmidt, B | 1 |
| Berellini, G; Cruciani, G; Mannhold, R | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Giridhar, R; Murumkar, P; Naik, P; Yadav, MR | 1 |
| Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Kiukaanniemi, K; Pelkonen, O; Taavitsainen, P | 1 |
| Grossman, E; Messerli, FH; Neutel, JM | 1 |
| Caballero, R; Delpón, E; González, T; Longobardo, M; Tamargo, J; Valenzuela, C | 1 |
| Vidt, DG | 1 |
| Ramahi, TM | 1 |
| Magometschnigg, D | 1 |
| Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA | 1 |
| Balt, JC; Mathy, MJ; Nap, A; Pfaffendorf, M; van Zwieten, PA | 2 |
| Rapi, J | 1 |
| Mancini, GB | 1 |
| Terra, SG | 1 |
| Jermendy, G; Matos, L; Winkler, G | 1 |
| Dominiak, P; Häuser, W | 1 |
| Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM | 1 |
| Dendorfer, A; Dominiak, P; Raasch, W; Tempel, K | 1 |
| Gremmler, B; Kisters, K; Kunert, M; Schleiting, H; Ulbricht, LJ | 1 |
| Asner, R; Bayer, A; Kopf, W; Letzel, M; Schüssler, W; Sengl, M; Weiß, K | 1 |
11 review(s) available for candesartan and eprosartan
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Growth Hormone; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Thromboxane A2 | 2003 |
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
Topics: Acrylates; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Drug Therapy, Combination; Heart; Humans; Hypertension; Imidazoles; Irbesartan; Kidney; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes | 2000 |
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Cardiovascular Diseases; Humans; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Metabolic Clearance Rate; Patient Selection; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Treatment Outcome; Valine; Valsartan | 2001 |
[Angiotensin receptor blockers--significance for the therapy of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Austria; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losartan; Prodrugs; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Valine; Valsartan | 2001 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Controlled Clinical Trials as Topic; Drug Administration Schedule; Enalapril; Half-Life; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2002 |
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary Artery Disease; Data Interpretation, Statistical; Diabetes Mellitus; E-Selectin; Endothelium, Vascular; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Thiophenes; Vasculitis | 2002 |
[Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Humans; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2004 |
1 trial(s) available for candesartan and eprosartan
| Article | Year |
|---|---|
Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.
Topics: Acrylates; Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; Biphenyl Compounds; Blood Pressure; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Telmisartan; Tetrazoles; Thiophenes; Treatment Outcome; Vascular Resistance | 2007 |
15 other study(ies) available for candesartan and eprosartan
| Article | Year |
|---|---|
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Structure-Activity Relationship; Tetrazoles | 2005 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents | 2011 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Imidazoles; In Vitro Techniques; Inhibitory Concentration 50; Irbesartan; Losartan; Microsomes, Liver; Protein Isoforms; Tetrazoles; Thiophenes; Valine; Valsartan | 2000 |
Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization.
Topics: Acrylates; Action Potentials; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cation Transport Proteins; Cell Line; CHO Cells; Cricetinae; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Heart Conduction System; Heart Ventricles; Humans; Imidazoles; In Vitro Techniques; KCNQ Potassium Channels; KCNQ1 Potassium Channel; Kv1.5 Potassium Channel; Mice; Papillary Muscles; Patch-Clamp Techniques; Potassium Channels; Potassium Channels, Voltage-Gated; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Shal Potassium Channels; Tetrazoles; Thiophenes; Trans-Activators; Transcriptional Regulator ERG | 2001 |
Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?
Topics: Acrylates; Angioedema; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Black or African American; Clinical Trials as Topic; Cough; Female; Humans; Imidazoles; Irbesartan; Losartan; Male; Randomized Controlled Trials as Topic; Sex Factors; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2001 |
Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Topics: Acrylates; Adrenergic alpha-Agonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Decerebrate State; Dihydropyridines; Dose-Response Relationship, Drug; Imidazoles; Male; Norepinephrine; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Sympathetic Nervous System; Synaptic Transmission; Tetrazoles; Thiophenes; Valine; Valsartan | 2001 |
Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Female; Imidazoles; In Vitro Techniques; Male; Mesenteric Arteries; Rabbits; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Presynaptic; Tetrazoles; Thiophenes | 2002 |
Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Imidazoles; In Vitro Techniques; Male; Presynaptic Terminals; Rabbits; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Vasoconstriction | 2003 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diuretics; Dizziness; Drug Combinations; Drug Interactions; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan | 2003 |
Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?
Topics: Acrylates; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Imidazoles; Irbesartan; Losartan; Male; Norepinephrine; Rats; Rats, Inbred SHR; Sympathetic Fibers, Postganglionic; Sympatholytics; Tetrazoles; Thiophenes; Time Factors; Treatment Outcome | 2005 |
Behavior of sartans (antihypertensive drugs) in wastewater treatment plants, their occurrence and risk for the aquatic environment.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biodegradation, Environmental; Biphenyl Compounds; Chromatography, Liquid; Environmental Monitoring; Germany; Imidazoles; Irbesartan; Mass Spectrometry; Molecular Structure; Rivers; Tetrazoles; Thiophenes; Valine; Valsartan; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2014 |